biotech · Chronic Hepatitis B · Chronic Hepatitis B Infection · ALGS
Aligos Therapeutics
Aligos Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker ALGS. Primary therapeutic focus areas include Chronic Hepatitis B, Chronic Hepatitis B Infection, Ch
1 Corporate Dr, South San Francisco, California 94080, US HQ
2018 Founded
98 Employees
Public company Type
ALGS · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1 Corporate Dr, South San Francisco, California 94080, US
- Founded
- 2018
- Employees
- 98
- Programs
- 14
- Drugs
- 10
- Patents
- 32
ALG-097558
Phase 1 · small molecule · COVID-19
ALG-097558 for COVID-19 is a Phase 1 program (small_molecule) at Aligos Therapeutics with 3 ClinicalTrials.gov record(s).
Internal code ALG-097558-702 / DMID 24-0001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Aligos Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- COVID-19
- Status
- completed
- Trials
- 3